glp 1 compounding ending New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our What Patients Need to Know

More recent research has explored BPC-157s effects on dopaminergic and serotonergic systems, traumatic brain injury models, and neuroprotection

Headquarters 1000 LOWES BLVD, MOORESVILLE, NC, 28117 Find & consolidate your 401(k)s We can find your old 401(k)s and move them to an IRA of your choice

Perhaps little known to some, Lilly actually has a fourth GLP-1 based molecule in late-stage studies, called brenipatide

The use of recombinant human growth hormone to protect against muscle weakness in patients undergoing anterior cruciate ligament reconstruction: A pilot, randomized placebo-controlled trial

Our injectors at Schaffer Skin specialize in administering this popular cosmetic treatment